Vascular endothelial growth factor in heart failure

Ziad Taimeh, John Loughran, Emma J. Birks, Roberto Bolli

Research output: Contribution to journalArticle

Abstract

Heart failure is a devastating condition, the progression of which culminates in a mismatch of oxygen supply and demand, with limited options for treatment. Heart failure has several underlying causes including, but not limited to, ischaemic heart disease, valvular dysfunction, and hypertensive heart disease. Dysfunctional blood vessel formation is a major problem in advanced heart failure, regardless of the aetiology. Vascular endothelial growth factor (VEGF) is the cornerstone cytokine involved in the formation of new vessels. A multitude of investigations, at both the preclinical and clinical levels, have garnered valuable information on the potential utility of targeting VEGF as a treatment option for heart failure. However, clinical trials of VEGF gene therapy in patients with coronary artery disease or peripheral artery disease have not, to date, demonstrated clinical benefit. In this Review, we outline the biological characterization of VEGF, and examine the evidence for its potential therapeutic application, including the novel concept of VEGF as adjuvant therapy to stem cell transplantation, in patients with heart failure.

Original languageEnglish (US)
Pages (from-to)519-530
Number of pages12
JournalNature Reviews Cardiology
Volume10
Issue number9
DOIs
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Heart Failure
Peripheral Arterial Disease
Stem Cell Transplantation
Therapeutics
Genetic Therapy
Myocardial Ischemia
Blood Vessels
Coronary Artery Disease
Heart Diseases
Clinical Trials
Cytokines
Oxygen

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Taimeh, Z., Loughran, J., Birks, E. J., & Bolli, R. (2013). Vascular endothelial growth factor in heart failure. Nature Reviews Cardiology, 10(9), 519-530. https://doi.org/10.1038/nrcardio.2013.94

Vascular endothelial growth factor in heart failure. / Taimeh, Ziad; Loughran, John; Birks, Emma J.; Bolli, Roberto.

In: Nature Reviews Cardiology, Vol. 10, No. 9, 09.2013, p. 519-530.

Research output: Contribution to journalArticle

Taimeh, Z, Loughran, J, Birks, EJ & Bolli, R 2013, 'Vascular endothelial growth factor in heart failure', Nature Reviews Cardiology, vol. 10, no. 9, pp. 519-530. https://doi.org/10.1038/nrcardio.2013.94
Taimeh, Ziad ; Loughran, John ; Birks, Emma J. ; Bolli, Roberto. / Vascular endothelial growth factor in heart failure. In: Nature Reviews Cardiology. 2013 ; Vol. 10, No. 9. pp. 519-530.
@article{aad55c91d4104d998ef51d15568c53b3,
title = "Vascular endothelial growth factor in heart failure",
abstract = "Heart failure is a devastating condition, the progression of which culminates in a mismatch of oxygen supply and demand, with limited options for treatment. Heart failure has several underlying causes including, but not limited to, ischaemic heart disease, valvular dysfunction, and hypertensive heart disease. Dysfunctional blood vessel formation is a major problem in advanced heart failure, regardless of the aetiology. Vascular endothelial growth factor (VEGF) is the cornerstone cytokine involved in the formation of new vessels. A multitude of investigations, at both the preclinical and clinical levels, have garnered valuable information on the potential utility of targeting VEGF as a treatment option for heart failure. However, clinical trials of VEGF gene therapy in patients with coronary artery disease or peripheral artery disease have not, to date, demonstrated clinical benefit. In this Review, we outline the biological characterization of VEGF, and examine the evidence for its potential therapeutic application, including the novel concept of VEGF as adjuvant therapy to stem cell transplantation, in patients with heart failure.",
author = "Ziad Taimeh and John Loughran and Birks, {Emma J.} and Roberto Bolli",
year = "2013",
month = "9",
doi = "10.1038/nrcardio.2013.94",
language = "English (US)",
volume = "10",
pages = "519--530",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Vascular endothelial growth factor in heart failure

AU - Taimeh, Ziad

AU - Loughran, John

AU - Birks, Emma J.

AU - Bolli, Roberto

PY - 2013/9

Y1 - 2013/9

N2 - Heart failure is a devastating condition, the progression of which culminates in a mismatch of oxygen supply and demand, with limited options for treatment. Heart failure has several underlying causes including, but not limited to, ischaemic heart disease, valvular dysfunction, and hypertensive heart disease. Dysfunctional blood vessel formation is a major problem in advanced heart failure, regardless of the aetiology. Vascular endothelial growth factor (VEGF) is the cornerstone cytokine involved in the formation of new vessels. A multitude of investigations, at both the preclinical and clinical levels, have garnered valuable information on the potential utility of targeting VEGF as a treatment option for heart failure. However, clinical trials of VEGF gene therapy in patients with coronary artery disease or peripheral artery disease have not, to date, demonstrated clinical benefit. In this Review, we outline the biological characterization of VEGF, and examine the evidence for its potential therapeutic application, including the novel concept of VEGF as adjuvant therapy to stem cell transplantation, in patients with heart failure.

AB - Heart failure is a devastating condition, the progression of which culminates in a mismatch of oxygen supply and demand, with limited options for treatment. Heart failure has several underlying causes including, but not limited to, ischaemic heart disease, valvular dysfunction, and hypertensive heart disease. Dysfunctional blood vessel formation is a major problem in advanced heart failure, regardless of the aetiology. Vascular endothelial growth factor (VEGF) is the cornerstone cytokine involved in the formation of new vessels. A multitude of investigations, at both the preclinical and clinical levels, have garnered valuable information on the potential utility of targeting VEGF as a treatment option for heart failure. However, clinical trials of VEGF gene therapy in patients with coronary artery disease or peripheral artery disease have not, to date, demonstrated clinical benefit. In this Review, we outline the biological characterization of VEGF, and examine the evidence for its potential therapeutic application, including the novel concept of VEGF as adjuvant therapy to stem cell transplantation, in patients with heart failure.

UR - http://www.scopus.com/inward/record.url?scp=84883144097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883144097&partnerID=8YFLogxK

U2 - 10.1038/nrcardio.2013.94

DO - 10.1038/nrcardio.2013.94

M3 - Article

VL - 10

SP - 519

EP - 530

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 9

ER -